“We are proud to welcome Dr. Bustamante to the NYCBS family,” said Jeff Vacirca, MD, CEO of NYCBS. “His expertise in molecular oncology will greatly benefit our patients and will play a pivotal role in advancing precision medicine at NYCBS.”
Dr. Bustamante has extensive expertise in molecular oncology and the treatment of various malignancies, specializing in thoracic oncology, including small-cell lung cancer, non-small cell lung cancer, mesothelioma, and thymic malignancies. He employs a comprehensive approach that integrates immunotherapy, targeted therapies, and diverse chemotherapy regimens…